Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1

摘要: There is a paucity of effective therapies for recurrent/aggressive meningiomas. Establishment improved in vitro and vivo meningioma models will facilitate development testing novel therapeutic approaches. A primary cell line was generated from patient with an olfactory groove meningioma. The extensively characterized by performing analysis growth kinetics, immunocytochemistry, telomerase activity, karyotype, comparative genomic hybridization. Xenograft using immunocompromised SCID mice were also developed. Histopathology the tumor consistent WHO grade I typical composed meningothelial cells, whorls, occasional psammoma bodies. original early passage cells shared standard immunohistochemical profile low-grade, good prognosis Low KCI-MENG1 two types spindle round morphologies, showed linear curve, had very low distinct unrelated clones on cytogenetic analysis. In contrast, high homogeneously round, rapidly growing, single clone near triploid karyotype containing 64–66 chromosomes numerous aberrations. Following subcutaneous orthotopic transplantation into mice, firm tumors positive vimentin progesterone receptor (PR) formed, while implant yielded vimentin-positive, PR-negative tumors, concordant high-grade Although derived benign specimen, newly-established spontaneously immortal can be utilized to generate xenograft either low- or features, dependent number (likely due relative abundance near-triploid cells). These human mouse provide biologically relevant platforms which investigate differences vs. biology disease progression as well develop improve treatment options poor recurrent